Sukhi Jagpal - Jan 28, 2022 Form 4 Insider Report for Sierra Oncology, Inc. (SRRA)

Role
Chief Financial Officer
Signature
/s/ Sukhi Jagpal / By: Mary Christina Thomson, Attorney-In-Fact
Stock symbol
SRRA
Transactions as of
Jan 28, 2022
Transactions value $
$0
Form type
4
Date filed
1/28/2022, 05:31 PM
Next filing
Mar 14, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SRRA Stock Option (Right to Buy) Award $0 +12.3K $0.00 12.3K Jan 28, 2022 Common Stock 12.3K $12.15 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On August 12, 2020, the Reporting Person was granted an option to purchase 49,000 shares of common stock. The option vests based on the satisfaction by Issuer of certain performance criteria. The achievement of one of the performance criteria resulted in vesting of the option as to 12,250 shares.